Diagnostik und Therapie der pulmonalen Hypertonie

Literatur

• 1 Barst R J, Langleben D, Frost A, Horn E M, Oudiz R, Shapiro S. et al . Sitaxsentan therapy for pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2004;  169 441-447
• 2 Barst R J, McGoon M, Torbicki A, Sitbon O, Krowka M J, Olschewski H. et al . Diagnosis and differential assessment of pulmonary arterial hypertension.  J Am Coll Cardiol. 2004;  (12 Suppl S) 43 40S-47S
• 3 Galie N, Badesch D, Oudiz R, Simonneau G, McGoon M D, Keogh A M. et al . Ambrisentan therapy for pulmonary arterial hypertension.  J Am Coll Cardiol. 2005;  46 529-535
• 4 Galie N, Ghofrani H A, Torbicki A, Barst R J, Rubin L J, Badesch D. et al . Sildenafil citrate therapy for pulmonary arterial hypertension.  N Engl J Med. 2005;  353 2148-2157
• 5 Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T. et al . Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.  Eur Heart J. 2004;  25 2243-2278
• 6 Ghofrani H A, Reichenberger F, Kohstall M G, Mrosek E H, Seeger T, Olschewski H. et al . Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial.  Ann Intern Med. 2004;  141 169-177
• 7 Ghofrani H A, Rose F, Schermuly R T, Olschewski H, Wiedemann R, Kreckel A. et al . Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.  J Am Coll Cardiol. 2003;  42 158-164
• 8 Ghofrani H A, Schermuly R T, Rose F, Wiedemann R, Kohstall M G, Kreckel A. et al . Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension.  Am J Respir Crit Care Med. 2003;  167 1139-1141
• 9 Hoeper M M, Kramm T, Wilkens H, Schulze C, Schafers H J, Welte T. et al . Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.  Chest. 2005;  128 2363-2367
• 10 Hoeper M M, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.  Eur Respir J. 2003;  22 330-334
• 11 Klepetko W, Mayer E, Sandoval J, Trulock E P, Vachiery J L, Dartevelle P. et al . Interventional and surgical modalities of treatment for pulmonary arterial hypertension.  J Am Coll Cardiol. 2004;  43 73S-80S (Suppl 12S)
• 12 Olschewski H, Ghofrani H A, Schmehl T, Winkler J, Wilkens H, Hoper M M. et al. German PPH Study Group . Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial.  Ann Intern Med. 2000;  132 435-443
• 13 Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin L J. et al . Inhaled iloprost for severe pulmonary hypertension.  N Engl J Med. 2002;  347 322-329
• 14 Rich S, Kaufmann E, Levy P S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.  N Engl J Med. 1992;  327 76-81
• 15 Rubin L J, Badesch D B, Barst R J, Galie N, Black C M, Keogh A. et al . Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
• 16 Simonneau G, Galie N, Rubin L J, Langleben D, Seeger W, Domenighetti G. et al . Clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2004;  43 (Suppl 12S) 5S-12S
• 17 Sitbon O, Humbert M, Jais X, Ioos V, Hamid A M, Provencher S. et al . Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.  Circulation. 2005;  111 3105-3111